Milestone Scientific (NYSE:MLSS) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Milestone Scientific (NYSE:MLSS) in a report published on Friday. The brokerage issued a hold rating on the stock.

Separately, Benchmark began coverage on shares of Milestone Scientific in a report on Thursday, October 10th. They set a “speculative buy” rating and a $1.25 price objective for the company.

Milestone Scientific Trading Down 2.1 %

MLSS stock opened at $0.78 on Friday. The stock has a market capitalization of $60.24 million, a PE ratio of -7.80 and a beta of 1.08. The stock’s 50 day simple moving average is $0.93 and its 200 day simple moving average is $0.82. Milestone Scientific has a 12-month low of $0.52 and a 12-month high of $1.10.

Milestone Scientific (NYSE:MLSS) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Milestone Scientific had a negative net margin of 54.87% and a negative return on equity of 60.78%. The business had revenue of $1.85 million for the quarter.

Insider Transactions at Milestone Scientific

In other Milestone Scientific news, Director Leonard Osser sold 107,984 shares of the stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $0.93, for a total value of $100,425.12. Following the transaction, the director now owns 4,606,882 shares of the company’s stock, valued at approximately $4,284,400.26. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 251,106 shares of company stock worth $236,451 in the last ninety days. Insiders own 24.75% of the company’s stock.

Milestone Scientific Company Profile

Milestone Scientific Inc, a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments.